Bioxytran (OTCMKTS:BIXT) Releases Earnings Results

Bioxytran (OTCMKTS:BIXT) posted its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Bioxytran Trading Down 15.4 %

Shares of Bioxytran stock traded down $0.02 during trading hours on Thursday, reaching $0.13. 245,639 shares of the company’s stock were exchanged, compared to its average volume of 278,622. The stock has a market cap of $11.10 million, a P/E ratio of -12.60 and a beta of 2.00. The company has a 50 day moving average of $0.11 and a two-hundred day moving average of $0.10. Bioxytran has a fifty-two week low of $0.06 and a fifty-two week high of $0.21.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.